US/UK/Canada

Share

Contacts

  • Bent U. Frandsen

    CEO


    +45 2222 1019
    http://www.expres2ionbio.com
  • Keith Alexander

    CFO


    +45 2222 1019
    http://www.expres2ionbio.com
    • Pick a time period -
    Tags ( Active)

    ExpreS2ion announces changes to leadership team

    Hørsholm, Denmark, 27 September 2023 - ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”), a pioneer in the development of innovative vaccines for a healthier world, today announced that Dr. Mattis Ranthe, Chief Medical Officer, and Dr. Mette Thorn, Senior Vice President of Preclinical Development, are stepping down from their positions in the Company following the future strategic focus on ExpreS2ion’s exploratory vaccine pipeline and technology platforms, as announced in press release of 17 August 2023. Dr. Ranthe will continue supporting the Company through the end of 2023 to

    Scientific article published about the Phase I clinical trial of the COVID-19 vaccine ABNCoV2

    Hørsholm, Denmark, January 20, 2023 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the journal The Lancet Microbe published an article about the COVID-19 vaccine candidate ABNCoV2 titled “First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2” co-authored by ExpreS2ion scientists.Abstract excerpt: “Immunisation with ABNCoV2 was well tolerated, safe, and resulted in a functional immune response. The data support the need for additional

    ExpreS2ion announces positive topline results for its HER2-cVLP breast cancer vaccine, demonstrating animal proof-of-concept

    Hørsholm, Denmark, December 22, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that its capsid virus-like particle (cVLP) breast cancer vaccine candidate ES2B-C001 demonstrated strong tumor-growth inhibiting effect in a mice model, thus reaching an important pre-clinical milestone ahead of schedule. Additionally, anti-HER2 antibodies from these studies were found to effectively inhibit tumor growth in human cancer cells. The therapeutic vaccine is being developed towards first in human clinical trials in 2023.The topline preclinical

    Pareto Securities and Analysguiden publish research reports with increased price targets of SEK 68 and SEK 55, respectively

    Hørsholm, Denmark, August 25, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in August. Pareto upheld its ‘buy’ rating with a target price of SEK 68 per share, while Analysguiden has set a new fair value of SEK 55 per share. Both of these reports were published before the August 23, 2021 announcement that the Danish Ministry of Health will fund the ABNCoV2 COVID-19 vaccine program with up to DKK 800 million.Both research reports are

    Positive safety and efficacy outcome of the COVID-19 clinical Phase I/II study for the ABNCoV2 vaccine

    Hørsholm, Denmark, August 09, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that COUGH-1, the COVID-19 Phase I/II clinical trial to evaluate the ABNCoV2 vaccine, as headline results has met its safety and efficacy endpoints with excellent virus neutralization levels of up to 12 times higher compared to the levels achieved after COVID-19 infection. This is significantly higher than the virus neutralization levels reported for leading mRNA COVID-19 vaccines reaching only up to 4.1 times higher than the levels achieved after COVID-19

    Lead candidate selected in ExpreS2ion’s HER2-cVLP breast cancer vaccine project

    Hørsholm, Denmark, May 11, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the selection of its lead candidate HER2-cVLP breast cancer vaccine. The project runs according to plan.ExpreS[2]ion, with the expert assistance of Prof. Pier Luigi Lollini at the Interdepartmental Center for Cancer Research, University of Bologna, has started the preclinical program, exploiting state-of-the-art in vitro and in vivo models mimicking some of the mechanisms in human breast cancer. As part of the preclinical program, ExpreS[2]ion has selected

    Publication of clinical Phase I/IIa data in the RH5 blood-stage malaria vaccine

    Hørsholm, Denmark, April 21, 2021 – ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and its protein production platform ExpreS2™ have contributed to a scientific article published in the journal Med. The article highlights the outcome of the VAC063-study, a Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium falciparum malaria vaccine candidate RH5.1/AS01\B\. In conclusion the RH5.1/AS01\B\ vaccine is safe, well tolerated, and immunogenic in healthy adults. A significantly reduced blood-stage parasite growth rate was observed in vaccinees

    Interim safety update on COUGH-1, the COVID-19 clinical phase I/II study for the ABNCoV2 vaccine

    Hørsholm, Denmark, April 12, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the first group of volunteers in the clinical Phase I/II study, COUGH-1, have been satisfactorily administered with the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine. The clinical study runs as planned with no untoward safety signal in now 18 healthy volunteers.The clinical Phase I/II study, COUGH-1, is designed to assess the power of the cVLP technology in combination with ExpreS[2]-made SARS-CoV2 antigens to safely induce a strong

    ExpreS2ion’s platform (ExpreS2) featured in Viruses article on O-glycosylation on SARS-CoV-2 spike protein

    ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and its protein production platform ExpreS2™ have contributed to a scientific article published in the journal Viruses. The article describes the site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells.The scientific article is entitled “Site-Specific O-Glycosylation Analysis of SARS-CoV-2 Spike Protein Produced in Insect and Human Cells”. Paper reference: Viruses 2021, 13(4), 551; https://doi.org/10.3390/v13040551, and can also be found at this link https://www.mdpi.com/1999-4915/13/4/551.

    Approval and initiation of the COVID-19 clinical phase I/II study for the ABNCoV2 vaccine

    Hørsholm, Denmark, March 8, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the clinical trial application (CTA) for a clinical phase I/II study for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been approved by the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands. The clinical study is now starting with the enrolment of up to 42 study participants to investigate safety and secondary efficacy parameters. First human dosing is planned for March 12, 2021. The CTA approval is

    Analysguiden announces new research report with the target price for ExpreS2ion at 24 SEK per share

    Hørsholm, Denmark, January 27, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case remains at 24 SEK per share.The major contributors of value in the sum-of-the-parts valuation are the PREVENT-nCoV COVID-19 vaccine program, now designated ABNCoV2 under exclusive license to Bavarian Nordic, and ExpreS[2]ion’s planned exercise of the option to inlicense the AV001/ES2B-C001 breast cancer vaccine candicate from its joint venture

    ExpreS2ion strengthens its organization to further accelerate its pipeline project development

    Hørsholm, Denmark, January 11, 2021 – ExpreS2ion Biotech Holding AB hereby announces that its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is reorganizing the company’s top management to reflect its increased strategic focus on pipeline development. Several appointments within research and development will ensure the advancement of ExpreS2ion’s development projects towards clinical investigations, with the first fully controlled project being the unique Her2-cVLP breast cancer project. This project will be in-licensed from ExpreS2ion’s joint venture AdaptVac ApS (“AdaptVac”) and

    ExpreS2ion announces submission of the COUGH-1 clinical trial application by the Prevent-nCoV consortium and Bavarian Nordic to review ABNCoV2

    Hørsholm, Denmark, January 8, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the clinical trial application (CTA) for a clinical Phase I/II study for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been submitted to the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands. The CTA is expected to be approved under a COVID-19 fast-track review procedure. The CTA submission is in line with the plans to present initial clinical Phase I/IIa results in Q1 2021.With the submission of

    ExpreS2ion publishes filmed scientific interview on the cVLP COVID-19 vaccine development

    ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed scientific talk on the development of the cVLP COVID-19 vaccine has been published on the company’s website. The video features Dr. Max M Søgaard from ExpreS2ion and Dr. Ali Salanti from ExpreS2ion’s joint venture and development partner AdaptVac.In the interview, Drs. Max M Søgaard and Ali Salanti talk about the rapid development process of the cVLP COVID-19 vaccine, and how it was made possible through a great collaborative effort between several industry entities and financiers.

    ExpreS2ion’s rights issue oversubscribed

    THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES IN ACCORDANCE WITH APPLICABLE LAW. Hørsholm, Denmark, October 23, 2020 – ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”) has completed the rights issue of shares and  warrants (“Units”)

    ExpreS2ion launches a new company website with increased focus on pipeline project development

    Hørsholm, Denmark, September 29, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces the launch of a significantly upgraded company website. The new website has a stronger focus on ExpreS2ion’s novel technology platforms and the company’s pipeline project development. It also introduces a separate investor site for improved communication with shareholders, potential investors and other parties of interest.Additional enhancements include easier access to ExpreS[2]ion’s online store, where customers are offered a broad range of viral antigens, transfection reagents and an

    ExpreS 2 ion Biotech Holding AB: Publication of interim report for January – June 2019

    ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes its interim report for the period January – June 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.CEO Steen Klysner comments “The sales and marketing activities initiated in 2018 are beginning to show significant results. Compared to H1 2018 ExpreS[2]ion is able to present a revenue growth of 34 %. During H1 2019 we also witnessed a large and continuous growth in our potential revenue pipeline. We expect to

    ExpreS2ion Biotechnologies Announces Research License Agreement with Mitsubishi Tanabe Pharma Corporation

    ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, has signed a two-year Research License Agreement granting Mitsubishi Tanabe Pharma Corporation access to use ExpreS2ion’s proprietary protein expression platform, ExpreS2 TM , in their Research and Development (R&D).The Research License Agreement The Research License Agreement grants Mitsubishi Tanabe Pharma Corporation the right to conduct research using ExpreS2ion’s proprietary ExpreS2system for two years.

    Report from Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)

    On the 19th of March 2019, an Extraordinary General Meeting in ExpreS2ion Biotech Holding AB was held. Below is a summary of the decisions that were taken. All decisions were taken with required majority.Please note that this report is an unofficial translation of a report from an Extraordinary General Meeting, originally written and published in Swedish. In case of discrepancies or differences between the Swedish original and the English translation, the Swedish original version shall prevail. Approval of the Board's decision on a directed issue The Extraordinary General Meeting

    ExpreS2ion co-publishes positive phase I placental malaria vaccine results from the PlacMalVac consortium

    ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the placental malaria vaccine (PlacMalVac) consortium, of which ExpreS2ion is part, has announced successful phase I clinical study results. The PAMVAC vaccine, manufactured using the ExpreS2 platform, was demonstrated to be safe, well-tolerated and to elicit specific antibody responses in all participants.The PlacMalVac project started in 2013 as an international consortium project funded by several parties (see below). The aim was to develop a vaccine against placental malaria,

    ExpreS2ion’s joint venture AdaptVac receives grants for two new projects: cardiovascular disease and breast cancer in dogs

    ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture AdaptVac ApS (“AdaptVac”) has received DKK 2.2 million (SEK 3.2 million) in funding from the Danish Innovation Foundation for two new vaccine development projects: cardiovascular disease (CVD) in humans and HER2+ breast cancer in dogs. The HER2+ dog project will also be used as preclinical studies for the ongoing HER2+ human breast cancer vaccine project AV001.The two grants, DKK 1 million for the cardiovascular disease vaccine project and DKK 1.2 million for the AV001 HER2+ breast cancer project, will cover two

    ExpreS2ion’s patent and research partner publishes malaria vaccine breakthrough in Nature

    ExpreS2ion Biotech Holding AB (“ExpreS2ion") announces the publication of the first visual image of the molecular ’key’ the deadliest malaria parasite uses to enter human blood cells in Nature. The publication was authored by an international team, including scientists from ExpreS2ion, led by the Walter and Eliza Hall Institute of Medical Research (“WEHI”). This breakthrough will contribute to the development of vaccines based on a patent co-owned equally by WEHI and ExpreS2ion.By creating a visualisation of this molecular ’key’ for the very first time, scientists now have access to the

    ExpreS2ion Biotech Holding AB: Publication of financial report for January – September 2018

    ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes the financial report for the period of January – September 2018. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.Q3 (2018-07-01 to 2018-09-30) · Group turnover amounted to 2,173 (2,048) KSEK. · Result after financial items amounted to -5,197 (-3,311) KSEK. · Net income amounted to -4,698 (-2,955) KSEK. · Net income per share* amounted to -0.39 (-0.33) SEK. Nine months (2018-01-01 to 2018-09-30) ·

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media